Have a feature idea you'd love to see implemented?
Let us know!
BLFS Biolife Solutions Inc
Price (delayed)
$25.39
Market cap
$1.18B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.72
Enterprise value
$1.19B
BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Its products and services portfolio includes its proprietary CryoStor® freeze media, HypoThermosol® shipping and storage
Highlights
The EPS has surged by 63% year-on-year and by 31% since the previous quarter
BLFS's net income has surged by 55% year-on-year and by 37% since the previous quarter
The debt has declined by 11% year-on-year but it has grown by 9% since the previous quarter
The company's revenue fell by 8% YoY but it rose by 6% QoQ
Key stats
What are the main financial stats of BLFS
Market
Valuations
Earnings
Shares outstanding
46.39M
Market cap
$1.18B
Enterprise value
$1.19B
Price to book (P/B)
3.6
Price to sales (P/S)
9.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.67
Revenue
$123.36M
EBIT
-$44.62M
EBITDA
-$35.11M
Free cash flow
$2.22M
Per share
Balance sheet
Liquidity
EPS
-$0.72
Free cash flow per share
$0.05
Book value per share
$7.05
Revenue per share
$2.67
TBVPS
$3
Total assets
$381.65M
Total liabilities
$56.19M
Debt
$39.27M
Equity
$325.46M
Working capital
$57.22M
Debt to equity
0.12
Current ratio
2.78
Quick ratio
1.63
Net debt/EBITDA
-0.43
Margins
Efficiency
Dividend
EBITDA margin
-28.5%
Gross margin
43%
Net margin
-37.3%
Operating margin
-22.7%
Return on assets
-11.7%
Return on equity
-14%
Return on invested capital
-35.9%
Return on capital employed
-12.8%
Return on sales
-36.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BLFS stock price
How has the Biolife Solutions stock price performed over time
Intraday
1.52%
1 week
17.27%
1 month
10.34%
1 year
86.28%
YTD
56.25%
QTD
1.4%
Financial performance
How have Biolife Solutions's revenue and profit performed over time
Revenue
$123.36M
Gross profit
$53M
Operating income
-$28.05M
Net income
-$46.03M
Gross margin
43%
Net margin
-37.3%
BLFS's operating income has soared by 70% YoY and by 36% QoQ
The operating margin has soared by 67% YoY and by 39% from the previous quarter
BLFS's net income has surged by 55% year-on-year and by 37% since the previous quarter
The net margin has surged by 51% year-on-year and by 41% since the previous quarter
Growth
What is Biolife Solutions's growth rate over time
Valuation
What is Biolife Solutions stock price valuation
P/E
N/A
P/B
3.6
P/S
9.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.67
The EPS has surged by 63% year-on-year and by 31% since the previous quarter
BLFS's price to book (P/B) is 29% higher than its last 4 quarters average of 2.8 and 6% higher than its 5-year quarterly average of 3.4
The P/S is 27% higher than the last 4 quarters average of 7.5 but 12% lower than the 5-year quarterly average of 10.8
The company's revenue fell by 8% YoY but it rose by 6% QoQ
Efficiency
How efficient is Biolife Solutions business performance
The ROE has soared by 52% YoY and by 37% from the previous quarter
The return on sales has surged by 51% year-on-year and by 41% since the previous quarter
Biolife Solutions's return on assets has surged by 50% YoY and by 36% QoQ
The ROIC has grown by 42% YoY and by 35% from the previous quarter
Dividends
What is BLFS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BLFS.
Financial health
How did Biolife Solutions financials performed over time
The total liabilities has decreased by 29% YoY but it has increased by 5% from the previous quarter
The total assets has decreased by 7% YoY
The debt is 88% smaller than the equity
The debt has declined by 11% year-on-year but it has grown by 9% since the previous quarter
Biolife Solutions's debt to equity has increased by 9% from the previous quarter but it has decreased by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.